Related Experiment Video

Updated: Aug 6, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Syk-dependent mTOR activation in follicular lymphoma cells

Ludivine Leseux1, Safouane M Hamdi, Talal Al Saati

  • 1INSERM U563-Centre de Physiopathologie Toulouse Purpan (CPTP), Département d'Oncogenèse et Signalisation dans les Cellules Hématopoïétiques, Centre Hospitalier Universitaire (CHU) Purpan-BP3028, Toulouse, France.

Blood
|August 17, 2006
PubMed

Insights

The Syk-mammalian target of rapamycin (mTOR) pathway is crucial for follicular lymphoma (FL) cell survival. Inhibiting Syk effectively reduces mTOR activity, suggesting Syk as a potential therapeutic target for B-cell lymphomas.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • The mammalian target of rapamycin (mTOR) pathway is a key regulator of cell growth and survival.
  • Dysregulation of mTOR signaling is implicated in various cancers, including B-cell lymphomas.
  • The specific mechanisms regulating mTOR in B-cell lymphomas are not fully understood.

Purpose of the Study:

  • To investigate the role of mTOR signaling in follicular lymphoma (FL).
  • To identify key regulators of mTOR activation in FL cells.
  • To evaluate the therapeutic potential of targeting the identified regulators in B-cell lymphomas.

Main Methods:

  • Immunohistochemistry on patient lymph node tissues and normal tonsillar tissues.
  • Analysis of mTOR pathway activation markers (p70S6 kinase, 4E-BP1) in FL cells.
  • Pharmacological and genetic inhibition of Syk, phospholipase D (PLD), and phosphatidylinositol 3-kinase (PI3K).

Main Results:

  • mTOR is active in FL cells, indicated by rapamycin-sensitive phosphorylation of p70S6 kinase and 4E-BP1.
  • Phosphorylated p70S6 kinase is elevated in FL tissues compared to normal tissues.
  • Syk expression and activity are significantly higher in FL cells than in normal or chronic lymphocytic leukemia B cells.
  • Syk activates mTOR through pathways independent of PLD and PI3K.
  • Inhibition of Syk potently suppressed mTOR activity in various B-cell lymphoma cell lines.

Conclusions:

  • The Syk-mTOR pathway plays a critical role in the survival of follicular lymphoma cells.
  • Syk acts as a key upstream activator of mTOR in FL, independent of PLD and PI3K.
  • Targeting Syk represents a promising therapeutic strategy for B-cell lymphomas, including FL, mantle cell lymphoma, Burkitt lymphoma, and diffuse large B-cell lymphoma.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...